Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03039413 · ClinicalTrials.gov registry record · Early Phase 1
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
A Early Phase 1 study of Urothelial Carcinoma and Bladder Urothelial Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03039413 is a Early Phase 1 study of Urothelial Carcinoma and Bladder Urothelial Carcinoma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 20 participants, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03039413, a Early Phase 1 study of Urothelial Carcinoma and Bladder Urothelial Carcinoma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies how well copper Cu-64 TP3805 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with urothelial cancer undergoing surgery or biopsy. Radioactive tracers, such as copper Cu-64 TP3805, may bind to tumor cells. PET/CT imaging performed with copper Cu-64 TP3805 may be a better way to detect urothelial cancer.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- DRUG Copper Cu 64 TP3805
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2024-07-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03039413
The ClinicalTrials.gov registry entry for NCT03039413 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.
NCT03039413 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03039413 about?
NCT03039413 is a clinical study titled "Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy". This pilot clinical trial studies how well copper Cu-64 TP3805 positron emission tomography (PET)/computed tomography (CT) works in imaging patients with urothelial cancer undergoing surgery or biopsy. Radioactive tracers, such as copper Cu-64 TP3805, may bind to tumor cells. PET/CT imaging performe...
What is the current status of trial NCT03039413?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2016-09-28. Estimated completion is 2024-07-19.
What conditions does trial NCT03039413 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Bladder Urothelial Carcinoma.
What interventions are being tested in trial NCT03039413?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Copper Cu 64 TP3805 (DRUG).
Who is sponsoring clinical trial NCT03039413?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03039413 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
RECRUITING · Early Phase 1
-
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
ACTIVE NOT RECRUITING · Early Phase 1
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.